Cargando…

Favorable immune checkpoint inhibitor outcome of patients with melanoma and NSCLC harboring FAT1 mutations

Immune checkpoint inhibitors (ICIs) are most commonly used for melanoma and non-small cell lung cancer (NSCLC) patients. FAT atypical cadherin 1 (FAT1), which frequently mutates in melanoma and NSCLC. In this study, we aim to investigate the association of FAT1 mutations with ICI response and outcom...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Wenjing, Tang, Yunfeng, Guo, Yuxian, Kong, Yujia, Shi, Fuyan, Sheng, Chao, Wang, Suzhen, Wang, Qinghua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9226130/ https://www.ncbi.nlm.nih.gov/pubmed/35739249 http://dx.doi.org/10.1038/s41698-022-00292-6

Ejemplares similares

SETBP1 mutation determines sensitivity to immune checkpoint inhibitors in melanoma and NSCLC
por: An, Fengxiao, et al.
Publicado: (2023)

Association of PTPRT mutations with immune checkpoint inhibitors response and outcome in melanoma and non‐small cell lung cancer
por: Zhang, Wenjing, et al.
Publicado: (2021)

Novel Molecular Determinants of Response or Resistance to Immune Checkpoint Inhibitor Therapies in Melanoma
por: Zhang, Wenjing, et al.
Publicado: (2022)

HSPG2 Mutation Association with Immune Checkpoint Inhibitor Outcome in Melanoma and Non-Small Cell Lung Cancer
por: Zhang, Wenjing, et al.
Publicado: (2022)

An aging‐related signature predicts favorable outcome and immunogenicity in lung adenocarcinoma
por: Zhang, Wenjing, et al.
Publicado: (2022)

Fatty Acid Synthase Mutations Predict Favorable Immune Checkpoint Inhibitor Outcome and Response in Melanoma and Non-Small Cell Lung Cancer Patients
por: Wang, Qinghua, et al.
Publicado: (2022)

Sex Disparities of Genomic Determinants in Response to Immune Checkpoint Inhibitors in Melanoma
por: Shi, Fuyan, et al.
Publicado: (2021)

Identification and Validation of RELN Mutation as a Response Indicator for Immune Checkpoint Inhibitor Therapy in Melanoma and Non-Small Cell Lung Cancer
por: Li, Zhenpeng, et al.
Publicado: (2022)

Immunological and clinical immunotherapy implications of NLRP3 mutations in melanoma
por: Wang, Qinghua, et al.
Publicado: (2021)

High mutation load, immune-activated microenvironment, favorable outcome, and better immunotherapeutic efficacy in melanoma patients harboring MUC16/CA125 mutations
por: Wang, Qinghua, et al.
Publicado: (2020)

Bioinformatic analysis identifies the immunological profile of turner syndrome with different X chromosome origins
por: Qi, Xiao, et al.
Publicado: (2023)

Association of clock-like mutational signature with immune checkpoint inhibitor outcome in patients with melanoma and NSCLC
por: Chong, Wei, et al.
Publicado: (2020)

Mutations in DNA damage response pathways as a potential biomarker for immune checkpoint blockade efficacy: evidence from a seven-cancer immunotherapy cohort
por: Zhang, Wenjing, et al.
Publicado: (2021)

Systemic Therapy for Oligoprogression in Patients with Metastatic NSCLC Harboring Activating EGFR Mutations
por: Rossi, Antonio, et al.
Publicado: (2022)

Adjuvant EGFR TKIs in NSCLC harboring EGFR mutations: looking for a consensus way
por: Attili, Ilaria, et al.
Publicado: (2020)

Phase 1 Clinical Trial of Trametinib and Ponatinib in Patients With NSCLC Harboring KRAS Mutations
por: Arbour, Kathryn C., et al.
Publicado: (2021)

Occult lymph node metastasis is not a favorable factor for resected NSCLC patients
por: Cai, Jing-Sheng, et al.
Publicado: (2023)

Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutation: an ambispective cohort study
por: Pu, Xingxiang, et al.
Publicado: (2023)

Optimal Treatments for NSCLC Patients Harboring Primary or Acquired MET Amplification
por: Sun, Dantong, et al.
Publicado: (2022)

Response to Afatinib in a Patient with NSCLC Harboring Novel EGFR Exon 20 Insertion Mutations
por: Lin, Ling, et al.
Publicado: (2020)

Efficacy of erlotinib in NSCLC harboring rare EGFR extracellular domain mutation (T263P) and common mutations: Case report and literature review
por: Wang, Qian, et al.
Publicado: (2022)

Efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer harboring BRAF mutations
por: Wang, Haowei, et al.
Publicado: (2023)

The Efficacy of Upfront Intracranial Radiation with TKI Compared to TKI Alone in the NSCLC Patients Harboring EGFR Mutation and Brain Metastases
por: Wang, Chunyu, et al.
Publicado: (2019)

Favorable outcome of patients with lung adenocarcinoma harboring POLE mutations and expressing high PD-L1
por: Liu, Liang, et al.
Publicado: (2018)

Inconsistent clinical outcomes following afatinib treatment in NSCLC patients harboring uncommon epidermal growth factor receptor mutation
por: Dong, Wei, et al.
Publicado: (2022)

Genomic Characterization of Concurrent Alterations in Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Mutations
por: Passaro, Antonio, et al.
Publicado: (2021)

Management of Oligoprogression in Patients with Metastatic NSCLC Harboring ALK Rearrangements
por: Pisano, Chiara, et al.
Publicado: (2022)

Plasma MiRNA alterations between NSCLC patients harboring Del19 and L858R EGFR mutations
por: Ma, Yihan, et al.
Publicado: (2016)

Chinese Medicine Combined With EGFR-TKIs Prolongs Progression-Free Survival and Overall Survival of Non-small Cell Lung Cancer (NSCLC) Patients Harboring EGFR Mutations, Compared With the Use of TKIs Alone
por: Wang, Yujia, et al.
Publicado: (2021)

ALK expression favorably impacts the prognosis of NRAS-mutated metastatic melanomas
por: Osella-Abate, Simona, et al.
Publicado: (2018)

Case Report: Afatinib Treatment in a Patient With NSCLC Harboring a Rare EGFR Exon 20 Mutation
por: Zöchbauer-Müller, Sabine, et al.
Publicado: (2021)

NF1‐mutated melanoma tumors harbor distinct clinical and biological characteristics
por: Cirenajwis, Helena, et al.
Publicado: (2017)

Insensitivity to T790M mutation? A pooled analysis of outcomes following osimertinib for the treatment of NSCLC patients harboring uncommon epidermal growth factor receptor mutation
por: Hu, Shanliang, et al.
Publicado: (2022)

An immunogenic NSCLC microenvironment is associated with favorable survival in lung adenocarcinoma
por: Givechian, Kevin B., et al.
Publicado: (2019)

Assessing the Survival Benefit of Surgery and Various Types of Radiation Therapy for Treatment of Hepatocellular Carcinoma: Evidence from the Surveillance, Epidemiology, and End Results Registries
por: Shi, Fuyan, et al.
Publicado: (2020)

Pathological complete response to immune checkpoint inhibitor in patients with colorectal cancer liver metastases harboring POLE exonuclease domain mutation
por: Wen, Lei, et al.
Publicado: (2022)

Association of PTPRD/PTPRT Mutation With Better Clinical Outcomes in NSCLC Patients Treated With Immune Checkpoint Blockades
por: Wang, Xiaoyan, et al.
Publicado: (2021)

SMO mutation predicts the effect of immune checkpoint inhibitor: From NSCLC to multiple cancers
por: Ji, Wenxiang, et al.
Publicado: (2022)

Afatinib in locally advanced/metastatic NSCLC harboring common EGFR mutations, after chemotherapy: a Phase IV study
por: Thongprasert, Sumitra, et al.
Publicado: (2019)

Outcomes of patients with stage III non-small cell lung cancer (NSCLC) that harbor a STK11 mutation
por: An, Josiah, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mlvr75sn8db0cmdlamf0hcf3be